Abstract
The neu oncogene is frequently found in certain types of human carcinomas and has been shown to be activated in animal models by nitrosourea-induced mutation. The activating mutation in the neu oncogene results in the substitution of a glutamic acid for a valine at position 664 in the transmembrane domain of the encoded protein product of 185 kda (designated p185), which, on the basis of homology studies, is presumed to be a receptor for an as yet unidentified growth factor. It has been proposed that activating amino acid substitutions in this region of p185 lead to a conformational change in the protein which causes signal transduction via an increase in tyrosine kinase activity in the absence of any external signal. Using conformational energy analysis, we have determined the preferred three-dimensional structures for the transmembrane decapeptide (residues 658-667) of the p185 protein with valine and glutamic acid at the critical position 664. The results indicate that the global minimum energy conformation of the decapeptide from the normal protein with Val at position 664 is an alpha-helix with a sharp bend (CD conformation at residues 664 and 665) in this region, whereas the global minimum conformation for the decapeptide from the mutant transforming protein with Glu at position 664 assumes an all alpha-helical configuration. Furthermore, the second highest energy conformation for the decapeptide from the normal protein is identical to the global minimum energy conformation for the decapeptide from the transforming protein, providing a possible explanation why overexpression of the normal protein also has a transforming effect.(ABSTRACT TRUNCATED AT 250 WORDS)
MeSH Terms
Amino Acid Sequence
Cell Membrane/analysis
Cell Transformation, Neoplastic
Glutamates
Glutamic Acid
Molecular Sequence Data
Oligopeptides
Protein Conformation
Proto-Oncogene Proteins
Receptor, ErbB-2
Structure-Activity Relationship
Thermodynamics
Valine
Chemicals
Glutamates
Oligopeptides
Proto-Oncogene Proteins
Glutamic Acid
Receptor, ErbB-2
Valine
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Brandt-Rauf P W
Department of Medicine, Columbia-Presbyterian Medical Center, New York, New York 10032.
Pincus M R
Chen J M
References (22)
22 references, click to expand
-
Neu receptor dimerization.
Nature. 1989 Jun 22;339(6226):587
PMID: 2567498
-
Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo.
Lancet. 1986 Apr 5;1(8484):765-7
PMID: 2870269
-
Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line.
Mol Cell Biol. 1986 Mar;6(3):955-8
PMID: 2430175
-
Use of a symmetry condition to compute the conformation of gramicidin S1.
Macromolecules. 1975 Nov-Dec;8(6):750-61
PMID: 53324
-
erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.
Science. 1987 Jul 10;237(4811):178-82
PMID: 2885917
-
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
Science. 1987 Jan 9;235(4785):177-82
PMID: 3798106
-
A point mutation in the neu oncogene mimics ligand induction of receptor aggregation.
Nature. 1989 May 18;339(6221):230-1
PMID: 2654648
-
Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185.
Cell. 1986 Jun 6;45(5):649-57
PMID: 2871941
-
Protein structure and cancer.
Cancer Invest. 1986;4(2):185-95
PMID: 3518878
-
Conformational analysis of the 20 naturally occurring amino acid residues using ECEPP.
Macromolecules. 1977 Jan-Feb;10(1):1-9
PMID: 839855
-
Structural effects of substitutions on the p21 proteins.
Proc Natl Acad Sci U S A. 1985 Jun;82(11):3596-3600
PMID: 3923480
-
Molecular cloning of the neu gene: absence of gross structural alteration in oncogenic alleles.
Proc Natl Acad Sci U S A. 1986 Jan;83(2):261-4
PMID: 3001730
-
Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion.
EMBO J. 1988 Jul;7(7):2043-52
PMID: 2901345
-
Calculation of the three-dimensional structure of the membrane-bound portion of melittin from its amino acid sequence.
Proc Natl Acad Sci U S A. 1982 Aug;79(16):5107-10
PMID: 6956920
-
p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity.
Mol Cell Biol. 1986 May;6(5):1729-40
PMID: 2878363
-
Prediction of the three-dimensional structure of the leader sequence of pre-kappa light chain, a hexadecapeptide.
Proc Natl Acad Sci U S A. 1982 Jun;79(11):3413-7
PMID: 6808509
-
Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.
Proc Natl Acad Sci U S A. 1987 Oct;84(20):7159-63
PMID: 2890160
-
Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts.
Nature. 1981 Mar 19;290(5803):261-4
PMID: 7207618
-
The neu oncogene encodes an epidermal growth factor receptor-related protein.
Nature. 1986 Jan 16-22;319(6050):226-30
PMID: 3945311
-
Amplification of a novel v-erbB-related gene in a human mammary carcinoma.
Science. 1985 Sep 6;229(4717):974-6
PMID: 2992089
-
A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma.
Proc Natl Acad Sci U S A. 1985 Oct;82(19):6497-501
PMID: 2995967
-
Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas.
Cell. 1982 Apr;28(4):865-71
PMID: 7094016